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Hypertension, defined as a systolic/diastolic blood
pressure of 140/90 mmHg or greater, is estimated to
carry a 3-fold increased risk of developing cardiovascular
disease (CVD), while treating hypertension significantly
reduces CVD events, and stroke in particular. Among the
many risk factors involved, there is much recent interest
in the role of genetic factors that might predispose to
hypertension.
Evidence from genome-wide association studies has
identified an association between blood pressure and the
gene encoding the folate-metabolising enzyme, methyle-
netetrahydrofolate reductase (MTHFR), while recent
meta-analyses of observational studies show an increased
risk of hypertension in people homozygous for the
677C®T polymorphism in MTHFR. Riboflavin (vitamin
B2) in the form of FAD acts as a cofactor for MTHFR
and we have been studying its modulating role in relation
to this polymorphism. The variant enzyme is known
from molecular studies to become inactive as a result of
having an increased propensity to dissociate from FAD,
but our earlier work suggested that supplementation with
low-dose riboflavin could stabilise MTHFR activity in
vivo in homozygous individuals. In recent years we
showed that CVD patients with the relevant MTHFR
677TT genotype (compared to CC or CT genotypes) had
significantly higher blood pressure, and that blood
pressure was highly responsive to riboflavin intervention,
specifically in the TT genotype group [1]. Further investi-
gations confirmed this gene-nutrient interaction in hyper-
tensive patients (with and without overt CVD), and
furthermore showed that the blood pressure lowering
effect of riboflavin in the TT genotype group was inde-
pendent of the number and type of antihypertensive
drugs that they were taking [2].
Although the precise mechanism linking this poly-
morphism to hypertension remains to be established, it
would appear that the biological perturbation that leads
to higher blood pressure in individuals with the MTHFR
677TT genotype is modifiable by correcting the variant
MTHFR enzyme through enhancing riboflavin status.
Thus riboflavin, targeted specifically at this genetically
at-risk group, may offer a personalized non-drug
approach to managing hypertension.
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